医药导报2024，Vol.43Issue(9)：1480-1486,7.DOI:10.3870/j.issn.1004-0781.2024.09.021
噻托溴铵/奥达特罗与噻托溴铵治疗中至极重度慢性阻塞性肺疾病的药物经济学评价
Economic Evaluation of Tiotropium/Olodaterol and Tiotropium in the Treatment of Moderate to Very Severe Chronic Obstructive Pulmonary Disease
顾雅婕 1张卓琳 2瞿庄茵 3杜林哲 3娄晟 3李歆 4朱君荣1
作者信息
- 1. 中国药科大学南京市第一医院药学部,南京 210006||南京医科大学附属南京医院(南京市第一医院)药学部,南京 210006
- 2. 南京医科大学药学院,南京 211166
- 3. 南京医科大学附属南京医院(南京市第一医院)药学部,南京 210006
- 4. 南京医科大学药学院,南京 211166||南京医科大学公共卫生学院全球健康中心,南京 211166
- 折叠
摘要
Abstract
Objective To evaluate the cost-utility of tiotropium/olodaterol in treating Chinese patients with moderate to very severe chronic obstructive pulmonary disease(COPD)and to provide references for selecting more economical inhaled preparations in clinical practice.Methods A four-state lifetime Markov model was established with a 3-month cycle.The health outcomes included life years and quality-adjusted life years.Costs,including direct medical costs,were calculated from the perspective of the Chinese health system.Discontinuation rates were derived from the discontinuation curve using GetData Graph Digitizer.The main output indicator of the model was the incremental cost-utility ratio,which was calculated from the queue simulation results to judge the economy of tiotropium bromide/odataterol.The scenario analysis and sensitivity analyses were carried out to detect the robustness of the base case result.Results Compared with tiotropium bromide,the patient treated with tiotropium bromide/odataterol gained an additional 0.0846 life years,an additional cost of ￥3 201.50,and additional 0.029 6 QALY.The incremental cost-utility ratio was 108 140.11 yuan/QALY,lower than the willingness-to-pay threshold of three times China's per capita GDP in 2021.The costs of tiotropium bromide and tiotropium bromide/odataterol had the greatest impact on the result in the one-way sensitivity analysis.93.8%of the Chinese COPD population was willing to pay for tiotropium bromide/odataterol under the threshold in the probability sensitivity analysis.Conclusion Tiotropium/olodaterol is a cost-effective alternative compared to tiotropium for patients with moderate to very severe COPD in China and the results were robust in the sensitivity analyses.关键词
噻托溴铵/奥达特罗/慢性阻塞性肺疾病/Markov模型/成本-效用分析Key words
Tiotropium/Olodaterol/Chronic obstructive pulmonary disease/Markov model/Cost-utility analysis分类
药学引用本文复制引用
顾雅婕,张卓琳,瞿庄茵,杜林哲,娄晟,李歆,朱君荣..噻托溴铵/奥达特罗与噻托溴铵治疗中至极重度慢性阻塞性肺疾病的药物经济学评价[J].医药导报,2024,43(9):1480-1486,7.
